MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Clinical trial NCT00094653 · COMPLETED

Trial details

NCT number: NCT00094653
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Melanoma Metastases

Start date: 2004-09-01
Primary completion: 2009-08-01
Enrollment: 1783

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.